Aim: Patient-reported outcomes associated with adverse events (AEs) reported with generics have not been evaluated. To map AEs associated with generics to the NIH Patient-reported Outcomes Measurement Information System.
Methods: We mapped 381 AEs from 148 case reports of generic tamsulosin, levothyroxine and amphetamine/dextroamphetamine to the physical, mental and social domain of the NIH Patient-Reported Outcomes Measurement Information System after reviewing 1237 case reports in the US FDA's Adverse Event Reporting System (FAERS; 2011-2013).
Results: 75%, 76% and 71% reports were classified under the physical domain for tamsulosin, levothyroxine and amphetamine/dextroamphetamine, while 9%, 9% and 18% reports were classified under the mental domain, respectively.
Conclusion: FAERS reveals several domains of patient-relevant concerns associated with generic drugs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819589 | PMC |
| http://dx.doi.org/10.2217/cer-2017-0006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A 68-Year-Old Man With Chronic Myelogenous Leukemia and a Large Unilateral Pleural Effusion.
Chest
February 2018
Respiratory Institute, Cleveland Clinic, Cleveland, OH.
A 68-year-old man with chronic myelogenous leukemia presents for evaluation of 2 months of dyspnea with exertion. He denies cough, fever, chest pain, weight gain, orthopnea, and edema. Since diagnosis of chronic myelogenous leukemia 5 years ago, he has been treated with dasatinib, with recent BCR-ABL1 assay showing no detectable disease in the peripheral blood.
View Article and Find Full Text PDFPatient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study.
J Comp Eff Res
July 2017
Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Aim: Patient-reported outcomes associated with adverse events (AEs) reported with generics have not been evaluated. To map AEs associated with generics to the NIH Patient-reported Outcomes Measurement Information System.
Methods: We mapped 381 AEs from 148 case reports of generic tamsulosin, levothyroxine and amphetamine/dextroamphetamine to the physical, mental and social domain of the NIH Patient-Reported Outcomes Measurement Information System after reviewing 1237 case reports in the US FDA's Adverse Event Reporting System (FAERS; 2011-2013).
An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System.
Drug Saf
September 2017
Department of Family Medicine and Community Health and Meyers Primary Care Institute, Umass Memorial Health Care, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA, 01655-0002, USA.
Introduction: Although generic drugs constitute approximately 88% of drugs prescribed in the US, there are no reliable methods to identify generic drugs in the US FDA Adverse Event Reporting System (FAERS).
Objective: The aim of this study was to develop an algorithm for identifying generic drugs in the FAERS.
Data Source: We used 1237 adverse event reports for tamsulosin, levothyroxine, and amphetamine/dextroamphetamine from the publicly available FAERS from 2011-2013, and 277 source case narratives obtained from the FDA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!